We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Micap | MIC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.375 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.375 | 0.375 |
| Top Posts |
|---|
Posted at 25/9/2006 10:30 by don muang ok ... I misread it slightly as read rns quickly ... (as also scanning thru other interesting rns's earlier this morning @rns-time : TPS, TER, LDC, PYF, SGM, LAF) ... so profit now 3 months later than planned as opposed to 3 months from now.I presume that's frustrating to investors that have been holding for a while. But personally for me I'm quite happy to wait as only bought in during this year as a long term play (as with its spread its a buy/hold rather than a trading opportunity). |
Posted at 02/8/2006 17:13 by elmura Looking up the latest news on this stock and recent developments seems to point to only one direction that this stock is worth picking and is at rock bottom price . I have invested a substantial sum based on the recent encouraging andpotential explosive news.Its time to jump in now before its too late . A cimpletely new investor . |
Posted at 08/2/2006 16:37 by arnoldlane Patrick Evershed owns Micap personally!!!For those that don't know, Patrick Evershed is the manager of New Star Select Opportunities Fund and previously the manager of Rathbones Special Situations Fund. He is a very well known small cap investor with an excellent long term track record. When he joined New Star his new fund was limited at £50m and was heavily oversubscribed. A personal holding is a major vote of confidence. I'd have thought these should move up on this news. al |
Posted at 07/2/2006 14:31 by hallucigenia have it on good authority that the 200k @4.7 was in fact a buyJP Morgan have had stock to sell at 4.6-ish when the spread was 4.5/5.0, so you can't read much into any of the trades until they've got rid of the rest of their holding. They had 3,275,909 shares (5.87%) at the time of their last RNS, so that's a fair old overhang for something as illiquid as Micap - and represents an opportunity for anyone with a good broker. Still, it's interesting to see a number of trades going through at substantially more than 4.6p, even though most of them are small investors getting mugged by the market. |
Posted at 09/11/2004 08:08 by beckaroo I thought the results read well with a good cash positive acquisition, good new applications of the technology and all current application still going strongly. However, the fact is that current stock market investors are very conservative and don't like start-up or loss making companies so I guess we are all in it for the long-haul. I trust the management to deliver. |
Posted at 20/10/2004 11:47 by rkjones Ok had a nibble this morning.Shareprice and chart simply does not reflect the good progress and positive announcements made over last few months. Should comfortably return to floatation price and if it finds favour with tipsheets/investors could retest 12m high.IMHO |
Posted at 23/8/2004 08:20 by beckaroo Good to see new investors Psyco. The days buying already beats other days when there has been news. I think the day the Skyephrama news was announced last week there was one or two trades, so should rocket with a bit more buying. Just to wet your appetite, this is from inpharma.com regarding Skyepharma dealSkyePharma takes up Micap option 18/08/2004 - Drug delivery specialist SkyePharma has decided to press ahead with the development of new drug products based on an encapsulation technology developed by fellow UK company Micap. After conducting preliminary testing, SkyePharma has decided to exercise its option to select for further development a number of pharmaceutical products that incorporate Micap's yeast-based system. Earlier this year, SkyePharma started looking at using Micap's technology for the delivery of hydrophobic drugs in up to 10 nominated pharmaceutical products. It has now selected the first of these products to take into further development, although its identity has not been disclosed for reasons of commercial confidentiality. Under the terms of the March agreement, ongoing royalties will be payable by SkyePharma to Micap on sales made, or licences of, any option product. SkyePharma will also make milestone payments on the first successful completion of Phase II and Phase III clinical trials and also on the first commercial launch of a product based on the technology. One of the key advantages of Micap's technology is that it can carry much higher concentrations of hydrophobic compounds which are poorly soluble and so hard to formulate - than other encapsulation methods. The technology does away with the need for solubilising additives, and can also combine additional compounds alongside active drugs in the same microcapsule. |
Posted at 17/8/2004 21:54 by beckaroo I see that Micap have the MRSA stuff in their August newsletter, via their website. All looks good promising stuff and the microencapsulated essential oil stuff looks applicable to many other areas. Also, This is from the SkyePharma board (thanks to AceUK), via Citywire:- First step for Micap and Skyepharma fails to excite Published: 11:36 Tue 17 Aug 2004 By Graeme Davies, Companies Correspondent Drug delivery specialist Skyepharma has chosen the first of a potential ten products to use the microencapsulation technology developed by Citywire tip Micap but the news has failed to budge the share price of either stock by much. The announcement brings the first crystallisation of a deal signed between the two companies in March which allows Skyepharma to use Micap's technology in up to ten products. The initial deal paid Micap £500,000 with further payments to come as products enter clinical trials and royalties will follow. Micap's shares (MIC) have added 0.5p to 44p this morning but Skyepharma's (SKP) are up 0.25p at 52.5p, just off their 2004 low of 50p. The link up between the two companies began last year when Skyepharma made a £2 million investment in Micap and Skyepharma founder Ian Gowrie-Smith became Micap's non-executive chairman. Frankly it would have been a bigger surprise to investors had Skyepharma not actually taken up Micap's technology for development within its own drug delivery systems, hence the rather lacklustre response from the market this morning. The true worth of the deal between the companies will only be seen when products start to progress through trials. Perhaps the reaction from investors would have been more enthusiastic had the companies deigned to tell us which product has been chosen but it has not been disclosed 'for reasons of commercial confidentiality.' Pharmaceutical developments are the third string to Micap's bow as it is already pushing its technology for use in food and herbicide applications. This technology involves the encapsulation of active ingredients in yeast cells which allows for selective release and protection from high temperatures and UV light. Citywire tipped Micap at 52.5p in January and as the vogue for small cap investment continued into the spring it rose as high as 83p but recently it has slipped back below the level at which we rated it a 'risky buy.' However we remain confident its bespoke technology will find its niche in the market and such investments are always likely to be choppy and to take some time to come to fruition. Skyepharma has been the perfect illustration of how uncertain conditions can be when investing in blue sky pharmaceutical companies. Its share price has fluctuated between 41.5p and 79p over the past 18 months as first the company made a maiden profit then slipped back into losses last year after failing to sign licensing deals before the end of the year. Both companies retain great potential and Skyepharma expects more products to hit the market this year. Newsflow is always important in supporting such companies' share prices and both will be hoping to report further progress from their tie-up throughout the coming months. ©2004 Citywire |
Posted at 28/4/2004 12:07 by chrismonty ok .. so I know it's a few weeks out of date but interesting to see what micap gets up to?Micap highlights research Apr 2 2004 Daily Post MERSEYSIDE bio-tech firm Micap yesterday held its first research day bringing together scientists, clients and investors. The Newton-le-Willows company, which specialises in the microencapsulation of active ingredients in yeast cells, hosted the event at Haydock Park Racecourse. Project managers from partners SkyePharma and flavour-fragrance house Firmenich attended, along with up to 40 scientists from Micap, its university partners and experts from the pharmaceutical, food and agricultural sectors. It looked specifically at how the company can further develop its technology for the benefit of the pharmaceutical, food and agricultural industries. The event came shortly after Micap announced its first licence agreement in pharmaceutical drug delivery, with SkyePharma worth more than £500,000. The exclusive licence will allow SkyePharma to use the technology in up to 10 pharmaceutical products. The company has recently secured more than £240,000 of research council and Dti funding. Good to see a bit of upward movement in the last few days too ! chris |
Posted at 04/3/2004 14:46 by tuffbet Could be some good exposure here for MICAP SkyePharma to Present at SG Cowen's 24th Annual Health Care Conference in Boston LONDON and NEW YORK, March 4 /PRNewswire-FirstCal announces today that the Company's Chief Executive Officer, Michael Ashton, will make a presentation at SG Cowen's 24th Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston, Massachusetts. Mr. Ashton will deliver his presentation on Thursday, March 11, 2004 at 8:00 a.m. (EST) and again at 9:00 a.m. (EST). Investors mayaccess a live webcast of the presentation at under the Investor Relations tab. About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now nine approved products incorporating three of SkyePharma's five technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. Formore information, visit DATASOURCE: SkyePharma PLC CONTACT: Michael Ashton, Chief Executive Officer, +44-207-491-1777, or Peter Laing, Director of Corporate Communications, +44-207-491-5124, or Sandra Haughton, US Investor Relations, +1-212-753-5780, all of SkyePharma PLC; or Tim Anderson or Mark Court, both of Buchanan Communications, +44-207-466-5000, for SkyePharma PLC Web site: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
